-
公开(公告)号：US20120053066A1
公开(公告)日：2012-03-01
申请号：US12918438
申请日：2009-02-19
申请人： Stephen J. Meltzer , Yulan Cheng , Zhe Jin
发明人： Stephen J. Meltzer , Yulan Cheng , Zhe Jin
CPC分类号： C12Q1/6886 , C12Q2600/154 , C12Q2600/156
摘要： This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).
摘要翻译： 本发明涉及例如用于预测受试者发生食管腺癌（EAC）或高度发育不良（HGD）的风险的方法，其包括在受试者的样品中测定各种组合的转录启动子区域的甲基化水平，其中 其他基因，（a）钙粘蛋白13，H钙粘蛋白（心脏）（CDH13）; （b）速激肽-1（TAC1）; （c）nel样1（NELL1）; （d）α-激酶锚定蛋白12（AKAP12）; （e）生长抑素（SST）; （f）具有EGF样的跨膜蛋白和两个卵泡抑素样结构域（HPP1）; （g）CDKN2a，细胞周期蛋白依赖性激酶抑制剂2a（p16）; 或（h）休克相关转录因子3（RUNX3）。
-
2.发明申请公开(公告)号：US20090111120A1
公开(公告)日：2009-04-30
申请号：US12295626
申请日：2007-03-30
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/154 , C12Q2600/156 , C12Q2600/16
摘要： The present invention provides methods for identifying or assessing probabilities for developing an abnormal condition in subject and for the recurrence of the abnormal condition in the subject after receiving treatment. The method comprises determining the methylation status of at least one gene in the subject and comparing this methylation status to normal methylation status. Differences between the methylation status of the one or more genes is indicative of the subject developing an abnormal condition or for the recurrence of the abnormal conditions after receiving treatment.
摘要翻译： 本发明提供了用于鉴定或评估在接受治疗后在受试者中发展异常状况和异常状况复发的概率的方法。 该方法包括确定受试者中至少一个基因的甲基化状态，并将该甲基化状态与正常甲基化状态进行比较。 一个或多个基因的甲基化状态之间的差异指示受试者在接受治疗后发展异常状况或异常状况的复发。
-
公开(公告)号：US08435490B2
公开(公告)日：2013-05-07
申请号：US12664302
申请日：2008-06-04
摘要： Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.
摘要翻译： 在不同恶性肿瘤中存在的突变的频率和类型方面，癌症是非常不均匀的。 因此，对于所有患者来说，统一的临床治疗可能不是最佳的，个体化治疗方案的发展可能是有益的。 多个独特的小肽结合来自不同结肠腺癌的细胞系。 在接触两小时后，结肠直肠癌细胞能够将32P放射性同位素从小肽转移到细胞蛋白质; 转移发生在比结肠直肠癌细胞中显着更高的速率，而不是来源于其他癌症或来自正常组织的细胞系。
-
4.发明申请Methylation of Gene Promoters as a Predictor of Effectiveness of Therapy 审中-公开基因启动子的甲基化作为治疗有效性的预测因子公开(公告)号：US20080299566A1
公开(公告)日：2008-12-04
申请号：US12097427
申请日：2006-12-18
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2523/125 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156
摘要： The present invention provides methods for identifying, diagnosing, evaluating or monitoring a disease state in a subject comprising identifying the methylation status of a panel of genes in the subject. The present invention also relates to identifying, diagnosing, evaluating or monitoring the responsiveness of a subject to a therapeutic regimen, with the methods comprising determining the methylation status of a panel of genes in the subject.
摘要翻译： 本发明提供用于鉴定，诊断，评估或监测受试者中疾病状态的方法，包括鉴定受试者中一组基因的甲基化状态。 本发明还涉及鉴定，诊断，评估或监测受试者对治疗方案的反应性，其方法包括测定受试者中一组基因的甲基化状态。
-
公开(公告)号：US09758833B2
公开(公告)日：2017-09-12
申请号：US12918438
申请日：2009-02-19
申请人： Stephen J. Meltzer , Yulan Cheng , Zhe Jin
发明人： Stephen J. Meltzer , Yulan Cheng , Zhe Jin
CPC分类号： C12Q1/6886 , C12Q2600/154 , C12Q2600/156
摘要： This invention relates, e.g., to methods for predicting a subject's risk for developing esophageal adenocarcinoma (EAC) or high-grade dysplasia (HGD), comprising determining in a sample from the subject the methylation levels of transcriptional promoter regions of various combinations of, among other genes, (a) cadherin 13, H-cadherin (heart) (CDH13); (b) tachykinin-1 (TAC1); (c) nel-like 1 (NELL1); (d) A-kinase anchoring protein 12 (AKAP12); (e) somatostatin (SST); (f) transmembrane protein with EGF-like and two follistatin-like domains (HPP1); (g) CDKN2a, cyclin-dependent kinase inhibitor 2a (p16); or (h) runt-related transcription factor 3 (RUNX3).
-
公开(公告)号：US20140031246A1
公开(公告)日：2014-01-30
申请号：US13811530
申请日：2011-07-22
申请人： Stephen J. Meltzer , Jee-Hoon Song , Yulan Cheng
发明人： Stephen J. Meltzer , Jee-Hoon Song , Yulan Cheng
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/178
摘要： The present invention relates to the field of biomarkers. More specifically, the present invention relates to the use of biomarkers to diagnose and monitor various diseases such as cancer.
摘要翻译： 本发明涉及生物标志物领域。 更具体地，本发明涉及生物标志物用于诊断和监测各种疾病如癌症的用途。
-
公开(公告)号：US08679759B2
公开(公告)日：2014-03-25
申请号：US12671406
申请日：2008-07-31
CPC分类号： C12Q1/6886 , G01N33/57407 , G06F19/20 , G06F19/34
摘要： The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer.
摘要翻译： 本发明涉及用于诊断受试者中的癌症的方法。 检测食管形态正常上皮细胞的标志物表达。 标志物的特征表达表明癌症的存在或癌症的易感性。 一组十一个标记物特别适用于鉴定癌症和癌症的倾向。
-
8.发明申请SERUM-BASED MIRNA MICROARRAY AND ITS USE IN DIAGNOSIS AND TREATMENT OF BARRETT'S ESOPHAGUS (BE) AND ESOPHAGEAL ADENOCARCINOMA (EAC) 审中-公开基于血清的MIRNA微阵列及其用于诊断和治疗BARRETT'S ESOPHAGUS（BE）和ESOPHAGEAL ADENOCARCINOMA（EAC）公开(公告)号：US20140031258A1
公开(公告)日：2014-01-30
申请号：US14008057
申请日：2012-03-26
申请人： Stephen J. Meltzer , Yulan Cheng , Jee-Hoon Song
发明人： Stephen J. Meltzer , Yulan Cheng , Jee-Hoon Song
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： Robust and reliable molecular diagnostic screening tools for early detection of esophageal and gastrointestinal tract cancers and pre-cancerous lesions, such as Barrett's Esophagus, and esophageal adenocarcinoma are provided. Included in the invention is an array of miRNA probes specific for identifying, diagnosing and prognosticating esophageal and gastrointestinal tract cancers and pre-cancerous lesions in subjects from blood or serum samples. A biochip comprising the array as well as methods for its use are also provided.
摘要翻译： 提供了用于早期检测食管和胃肠道癌症以及癌前病变（如Barrett食管）和食道腺癌的可靠和可靠的分子诊断筛选工具。 本发明中包括一系列miRNA探针，其特异性用于鉴定，诊断和预测来自血液或血清样品的受试者的食道和胃肠道癌症以及癌前病变。 还提供了包括阵列的生物芯片以及其使用方法。
-
公开(公告)号：US20100285466A1
公开(公告)日：2010-11-11
申请号：US12671406
申请日：2008-07-31
CPC分类号： C12Q1/6886 , G01N33/57407 , G06F19/20 , G06F19/34
摘要： The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer.
摘要翻译： 本发明涉及用于诊断受试者中的癌症的方法。 检测食管形态正常上皮细胞的标志物表达。 标志物的特征表达表明癌症的存在或癌症的易感性。 一组十一个标记物特别适用于鉴定癌症和癌症的倾向。
-
公开(公告)号：US20100183511A1
公开(公告)日：2010-07-22
申请号：US12664302
申请日：2008-06-04
摘要： Cancers are extremely heterogeneous in terms of the frequency and types of mutations present in different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. Multiple, unique small peptides bind to cell lines derived from different colon adenocarcinomas. Within two hours of contact, the colorectal cancer cells are able to transfer a 32P radioisotope from the small peptides to cellular proteins; the transfer occurs at a substantially higher rate than in the colorectal cancer cells than in cell lines derived from other cancers or from normal tissues.
摘要翻译： 在不同恶性肿瘤中存在的突变的频率和类型方面，癌症是非常不均匀的。 因此，对于所有患者来说，统一的临床治疗可能不是最佳的，个体化治疗方案的发展可能是有益的。 多个独特的小肽结合来自不同结肠腺癌的细胞系。 在接触两小时后，结肠直肠癌细胞能够将32P放射性同位素从小肽转移到细胞蛋白质; 转移发生在比结肠直肠癌细胞中显着更高的速率，而不是来源于其他癌症或来自正常组织的细胞系。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.017 秒)